Switch to dolutegravir and unboosted atazanavir in HIV-1 infected patients with undetectable viral load and long exposure to antiretroviral therapy

MLA

Castagna, A., et al. Switch to Dolutegravir and Unboosted Atazanavir in HIV-1 Infected Patients with Undetectable Viral Load and Long Exposure to Antiretroviral Therapy. 2019. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsoai&AN=edsoai.on1145017033&authtype=sso&custid=ns315887.

APA

Castagna, A., Rusconi, S., Gulminetti, R., Bonora, S., Mazzola, G., Quiros-Roldan, M. E., De Socio, G. V., Ladisa, N., Carosella, S., Cattelan, A., Di Giambenedetto, S., Mena, M., Poli, A., Galli, L., Riva, A., & Di Giambenedetto S. (ORCID:0000-0001-6990-5076). (2019). Switch to dolutegravir and unboosted atazanavir in HIV-1 infected patients with undetectable viral load and long exposure to antiretroviral therapy.

Chicago

Castagna, A., S. Rusconi, R. Gulminetti, S. Bonora, G. Mazzola, M. E. Quiros-Roldan, G. V. De Socio, et al. 2019. “Switch to Dolutegravir and Unboosted Atazanavir in HIV-1 Infected Patients with Undetectable Viral Load and Long Exposure to Antiretroviral Therapy.” http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsoai&AN=edsoai.on1145017033&authtype=sso&custid=ns315887.